FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156836360> ?p ?o ?g. }

• W2156836360 endingPage "580" @default.
• W2156836360 startingPage "577" @default.
• W2156836360 abstract "Oral etoposide is an active single agent in small-cell lung cancer (SCLC) and is widely prescribed as first-line treatment as an alternative to intravenous combination chemotherapy in patients with extensive disease.The intention of this study was to determine if the effects of oral etoposide therapy on survival and quality of life are equivalent to those of intravenous chemotherapy.In a randomized trial of palliative treatment in advanced SCLC, oral etoposide (100 mg given twice daily for 5 days) was compared with intravenous chemotherapy consisting of alternating cycles of cisplatin and etoposide (PE) and cyclophosphamide, doxorubicin, and vincristine (CAV). Six cycles of chemotherapy were administered every 21 days in both regimens. Symptom control and quality of life were measured with the Rotterdam Symptom Checklist and a daily diary card. In January 1996, after 155 patients had been randomly assigned from a projected intake of 365 patients, an independent Data Monitoring Committee examined the interim results. Survival was determined by the Kaplan-Meier method, and the logrank test was used to compare treatments. For quality-of-life comparisons, average scores were calculated for each time point. The Mann-Whitney U test was used to determine any significant overall differences between treatments. For the Rotterdam Symptom Checklist, separate analyses were done for each subset (psychological well-being, physical symptoms, lung cancer symptoms, treatment symptoms, activity, and quality of life). Response rates and toxicity scores were compared by using chi2. All statistical tests were two-sided.Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival. Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy. Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01). With the exception of acute nausea and vomiting associated with intravenous chemotherapy, all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group. Study closure was recommended.These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease." @default.
• W2156836360 created "2016-06-24" @default.
• W2156836360 creator A5011734499 @default.
• W2156836360 creator A5029727924 @default.
• W2156836360 creator A5039491597 @default.
• W2156836360 creator A5052620856 @default.
• W2156836360 creator A5061060832 @default.
• W2156836360 creator A5062675479 @default.
• W2156836360 creator A5069406714 @default.
• W2156836360 creator A5081623468 @default.
• W2156836360 date "1997-04-16" @default.
• W2156836360 modified "2023-10-16" @default.
• W2156836360 title "Five-Day Oral Etoposide2 Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy" @default.
• W2156836360 cites W1605816160 @default.
• W2156836360 cites W1970325604 @default.
• W2156836360 cites W1990319149 @default.
• W2156836360 cites W2010337166 @default.
• W2156836360 cites W2039123736 @default.
• W2156836360 cites W2089920620 @default.
• W2156836360 cites W2154060376 @default.
• W2156836360 cites W2236604469 @default.
• W2156836360 cites W2260882318 @default.
• W2156836360 cites W296967391 @default.
• W2156836360 doi "https://doi.org/10.1093/jnci/89.8.577" @default.
• W2156836360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9106647" @default.
• W2156836360 hasPublicationYear "1997" @default.
• W2156836360 type Work @default.
• W2156836360 sameAs 2156836360 @default.
• W2156836360 citedByCount "188" @default.
• W2156836360 countsByYear W21568363602012 @default.
• W2156836360 countsByYear W21568363602013 @default.
• W2156836360 countsByYear W21568363602014 @default.
• W2156836360 countsByYear W21568363602015 @default.
• W2156836360 countsByYear W21568363602016 @default.
• W2156836360 countsByYear W21568363602017 @default.
• W2156836360 countsByYear W21568363602018 @default.
• W2156836360 countsByYear W21568363602019 @default.
• W2156836360 countsByYear W21568363602020 @default.
• W2156836360 countsByYear W21568363602021 @default.
• W2156836360 countsByYear W21568363602022 @default.
• W2156836360 countsByYear W21568363602023 @default.
• W2156836360 crossrefType "journal-article" @default.
• W2156836360 hasAuthorship W2156836360A5011734499 @default.
• W2156836360 hasAuthorship W2156836360A5029727924 @default.
• W2156836360 hasAuthorship W2156836360A5039491597 @default.
• W2156836360 hasAuthorship W2156836360A5052620856 @default.
• W2156836360 hasAuthorship W2156836360A5061060832 @default.
• W2156836360 hasAuthorship W2156836360A5062675479 @default.
• W2156836360 hasAuthorship W2156836360A5069406714 @default.
• W2156836360 hasAuthorship W2156836360A5081623468 @default.
• W2156836360 hasBestOaLocation W21568363601 @default.
• W2156836360 hasConcept C126322002 @default.
• W2156836360 hasConcept C141071460 @default.
• W2156836360 hasConcept C168563851 @default.
• W2156836360 hasConcept C2776256026 @default.
• W2156836360 hasConcept C2776694085 @default.
• W2156836360 hasConcept C2776755627 @default.
• W2156836360 hasConcept C2776907518 @default.
• W2156836360 hasConcept C2778119113 @default.
• W2156836360 hasConcept C2779429289 @default.
• W2156836360 hasConcept C71924100 @default.
• W2156836360 hasConceptScore W2156836360C126322002 @default.
• W2156836360 hasConceptScore W2156836360C141071460 @default.
• W2156836360 hasConceptScore W2156836360C168563851 @default.
• W2156836360 hasConceptScore W2156836360C2776256026 @default.
• W2156836360 hasConceptScore W2156836360C2776694085 @default.
• W2156836360 hasConceptScore W2156836360C2776755627 @default.
• W2156836360 hasConceptScore W2156836360C2776907518 @default.
• W2156836360 hasConceptScore W2156836360C2778119113 @default.
• W2156836360 hasConceptScore W2156836360C2779429289 @default.
• W2156836360 hasConceptScore W2156836360C71924100 @default.
• W2156836360 hasIssue "8" @default.
• W2156836360 hasLocation W21568363601 @default.
• W2156836360 hasLocation W21568363602 @default.
• W2156836360 hasOpenAccess W2156836360 @default.
• W2156836360 hasPrimaryLocation W21568363601 @default.
• W2156836360 hasRelatedWork W118279503 @default.
• W2156836360 hasRelatedWork W1942971125 @default.
• W2156836360 hasRelatedWork W2047930003 @default.
• W2156836360 hasRelatedWork W2063116093 @default.
• W2156836360 hasRelatedWork W2121694206 @default.
• W2156836360 hasRelatedWork W2122995772 @default.
• W2156836360 hasRelatedWork W2252336101 @default.
• W2156836360 hasRelatedWork W2401224456 @default.
• W2156836360 hasRelatedWork W2412181118 @default.
• W2156836360 hasRelatedWork W4255778788 @default.
• W2156836360 hasVolume "89" @default.
• W2156836360 isParatext "false" @default.
• W2156836360 isRetracted "false" @default.
• W2156836360 magId "2156836360" @default.
• W2156836360 workType "article" @default.